{"id":"W4415942743","doi":"10.1016/j.annonc.2025.08.1751","title":"1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; Endometrial cancer; Exploratory analysis; Progression-free survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001498936,0.00076513,0.001641112,0.0003293329,0.0002865376,0.001011671,0.0006916071,0.0009785859,0.00510028],"category_scores_gemma":[0.001428063,0.0002917247,0.002818843,0.0003996653,0.0003585988,0.001316792,0.0003785511,0.002449028,0.0007669645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001066841,"about_ca_system_score_gemma":0.0009538266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002982187,"about_ca_topic_score_gemma":0.007516367,"domain_scores_codex":[0.9992543,0.0002736018,0.00003766101,0.0001705989,0.00006019148,0.0002036421],"domain_scores_gemma":[0.9990767,0.0002930342,0.0002134938,0.00009977529,0.00004154318,0.0002753503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8778848,0.010669,0.01778143,0.0005509042,0.005512668,0.0001265747,0.00008215046,0.002238914,0.00419969,0.0001781366,0.004281248,0.07649458],"study_design_scores_gemma":[0.2898217,0.4112467,0.2619822,0.0003617261,0.01702707,0.00047826,0.0003511375,0.005422193,0.004026276,0.0009211381,0.008249452,0.0001121806],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988696,0.004044905,0.0001875047,0.0004908352,0.0002009275,0.0001941211,0.003806246,0.00004723162,0.002332228],"genre_scores_gemma":[0.9878144,0.002129309,0.0003897745,0.0007736134,0.0001700515,0.0002210373,0.005419025,0.00002163262,0.003061087],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00510028,"threshold_uncertainty_score":0.01706213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09508130975977898,"score_gpt":0.409851283042694,"score_spread":0.3147699732829151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}